YSTH2

Drug Profile

YSTH2

Alternative Names: Anthy2; Research programme: Th2 cytokines synthesis inhibitor - Y's Therapeutics; Th2 cytokines synthesis inhibitor - Y's Therapeutics; YSTH2-O-AS

Latest Information Update: 23 Sep 2009

Price : $50

At a glance

  • Originator Ys Therapeutics
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Cytokine inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma; Atopic dermatitis

Most Recent Events

  • 19 Jul 2005 Phase-II clinical trials in Asthma in Germany (PO)
  • 28 Jul 2004 Discontinued - Preclinical for Atopic dermatitis in Japan (Topical)
  • 27 Jul 2004 Y's Therapeutics has filed an application to begin phase II trials with the Ministry of Health in Germany for Asthma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top